Pros | ![]() 3Y returns in the top 25% of the category. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | ![]() 5Y returns in the bottom 25% of the category. ![]() 3Y returns in the bottom 25% of the category. |
INDMoney rank | 6/8 | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 12 Years | 12 Years | ||
Fund Size | 1146 Cr | 8737 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 1.26% | 0.89% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 43 | 41 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (9.84%) Cipla Ltd (5.43%) Ajanta Pharma Ltd (4.8%) Lupin Ltd (4.29%) Procter & Gamble Health Ltd (4.13%) | Sun Pharmaceuticals Industries Ltd (12.22%) Divi's Laboratories Ltd (7.55%) Lupin Ltd (5.93%) Cipla Ltd (5.69%) Dr Reddy's Laboratories Ltd (5.69%) | ||
No of Sectors | 2 | 1 | ||
Top 3 Sectors | Health (98.94%) Basic Materials (1.06%) | Health (100%) | ||
Equity % | 97.66% | 99.45% | ||
Debt % | - | - | ||
P/E | 39.37 | 37.97 | ||
P/B | 5.98 | 6.05 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 0.92% | 0.06% | ||
3-Month Return | 5.06% | 1.2% | ||
6-Month Return | 15.83% | 11.11% | ||
1-Year Return | 3.68% | -0.73% | ||
3-Year Return | 26.99% | 24.25% | ||
5-Year Return | 20.3% | 20.09% |
Sharpe | 1.15 | 1.06 | ||
Alpha | 2.02 | 0.66 | ||
Beta | 0.95 | 0.91 | ||
Standard Deviation | 15.67 | 15.05 | ||
Information Ratio | 0.5 | -0.24 |
Description | UTI Healthcare Fund-Growth Option- Direct is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Kamal Gada | Sailesh Raj Bhan,Kinjal Desai |